A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

NCT06155487 | Enrolling By Invitation Phase 1 DMC

• 1 other identifier: AJH-2947_101
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

Preliminary evaluate of pharmacokinetics, pharmacodynamics, safety and tolerability after oral administration of AJH-2947 in healthy Korean or Caucasian male subjects

Conditions

Neuropathic Pain; Diabetic Neuropathies; Post Herpetic Neuralgia

Keywords

Neuropathic Pain; TRPV1 antagonist; Phase 1

Outcome Measures

Primary Outcomes (13)

• Part A (SAD): Plasma concentrations of AJH-2947

  To characterize the plasma concentration of AJH-2947 after single oral dosing in healthy Korean and Caucasian male participants.

  Day 1 to Day 5

• Part A (SAD): Urine concentrations of AJH-2947

  To characterize the urine concentration of AJH-2947 after single oral dosing in healthy Korean and Caucasian male participants.

  Day 1 to Day 4

• Part A (SAD): Maximum observed concentration [Cmax]

  To characterize the Cmax of AJH-2947 after single oral dosing in healthy Korean and Caucasian male participants

  Day 1 to Day 5

• Part A (SAD): Area under concentration curve from time 0 to the last quantifiable concentration [AUClast]

  To characterize the AUClast of AJH-2947 after single oral dosing in healthy Korean and Caucasian male participants.

  Day 1 to Day 5

• Part A (SAD): Time to reach peak or maximum observed concentration [Tmax]

  To characterize the Tmax of AJH-2947 after single oral dosing in healthy Korean and Caucasian male participants.

  Day 1 to Day 5

• Part B (MAD): Plasma concentrations of AJH-2947

  To characterize the plasma concentration of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): Maximum observed concentration [Cmax]

  To characterize the Cmax of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): The partial area from dosing time to dosing time plus dosing interval [AUCτ]

  To characterize the AUCτ of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): Time of maximum observed concentration [Tmax]

  To characterize the Tmax of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): Maximum observed concentration occurring at time Tmax,ss [Cmax,ss]

  To characterize the Cmax,ss of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): At steady state, the partial area from dosing time to dosing time plus dosing interval [AUCτ,ss]

  To characterize the AUCτ,ss of AJH-2947 following oral administration of multiple ascending doses in healthy Korean and Caucasian male participants.

  Day 1 to Day 18

• Part B (MAD): Heat pain Threshold (The temperature at which the subject first perceives pain, ℃)

  Heat pain Threshold is determined by gradually increased the temperature of the thermal probe on non-sensitized and casaicin-sensitized skin starting from 30 ℃ as the baseline using Thermal NeuroSensory Analyzer. (The cutoff limit is set at 50°C)

  Predose, Day 1, Day 7, and Day 8

• Part B (MAD): Heat pain tolerance (The Maximum temperature that the subject can tolerate, ℃)

  Heat pain tolerance is determined by gradually increased the temperature of the thermal probe on non-sensitized and casaicin-sensitized skin starting from 30 ℃ as the baseline using Thermal NeuroSensory Analyzer. (The cutoff limit is set at 50°C)

  Predose, Day 1, Day 7, and Day 8

Secondary Outcomes (4)

• Part A (SAD): Number of participants with adverse events (AE)

  Day -1, Day 1 to day 12 (last visit)

• Part A (SAD): Number of participants with serious adverse events (SAE)

  Day -1, Day 1 to day 18 (last visit)

• Part B (MAD): Number of participants with AE

  Day -1, Day 1 to day 18 (last visit)

• Part B (MAD): Number of participants with SAE

  Day -1, Day 1 to day 18 (last visit)

Study Arms (9)

(Part A) Single dose group 1

EXPERIMENTAL

Oral dose of AJH-2947/placebo 100 mg, Korean Only\*

Drug: AJH-2947 100 mg (SAD); Drug: Placebo

(Part A) Single dose group 2

EXPERIMENTAL

Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian

Drug: AJH-2947 200 mg (SAD); Drug: Placebo

(Part A) Single dose group 3

EXPERIMENTAL

Oral dose of AJH-2947/placebo 300 mg, Korean and Caucasian

Drug: AJH-2947 300 mg (SAD); Drug: Placebo

(Part A) Single dose group 4

EXPERIMENTAL

Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian

Drug: AJH-2947 400 mg (SAD); Drug: Placebo

(Part A) Single dose group 5

EXPERIMENTAL

Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian

Drug: AJH-2947 600 mg (SAD); Drug: Placebo

(Part A) Single dose group 6

EXPERIMENTAL

Oral dose of AJH-2947/placebo 800 mg, Korean and Caucasian

Drug: AJH-2947 800 mg (SAD); Drug: Placebo

(Part B) Multiple dose group 1

EXPERIMENTAL

Oral dose of AJH-2947/placebo 200 mg, Korean and Caucasian

Drug: AJH-2947 200 mg (MAD); Drug: Placebo

(Part B) Multiple dose group 2

EXPERIMENTAL

Oral dose of AJH-2947/placebo 400 mg, Korean and Caucasian

Drug: AJH-2947 400 mg (MAD); Drug: Placebo

(Part B) Multiple dose group 3

EXPERIMENTAL

Oral dose of AJH-2947/placebo 600 mg, Korean and Caucasian

Drug: AJH-2947 600 mg (MAD); Drug: Placebo

Interventions

AJH-2947 100 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 100 mg

(Part A) Single dose group 1

Placebo DRUG

Oral Tablet, Single dose of Placebo 100 mg

(Part A) Single dose group 1

AJH-2947 200 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 200 mg

(Part A) Single dose group 2

AJH-2947 300 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 300 mg

(Part A) Single dose group 3

AJH-2947 400 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 400 mg

(Part A) Single dose group 4

AJH-2947 600 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 600 mg

(Part A) Single dose group 5

AJH-2947 800 mg (SAD) DRUG

Oral Tablet, Single dose of AJH-2947 800 mg

(Part A) Single dose group 6

AJH-2947 200 mg (MAD) DRUG

Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg

(Part B) Multiple dose group 1

AJH-2947 400 mg (MAD) DRUG

Oral Tablet,Multiple (once daily for 7days) oral dose of AJH-2947 400 mg

(Part B) Multiple dose group 2

AJH-2947 600 mg (MAD) DRUG

Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 600 mg

(Part B) Multiple dose group 3

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Korean or Caucasian adult males aged 19 to 55 years old, based on the date of written consent
• \*Caucasian subjects = Individuals born in Europe, have resided in countries outside Europe for less than 10 years, and whose parents and grandparents are all of European descent.
• Individuals with a body weight between 50.0 kg and 90.0 kg and a body mass index (BMI) ranging from 18.5 kg/m2 to less than 30.0 kg/m2
• \- BMI (kg/m2) = weight (kg) / {height (m)}2
• Individuals who agree to stay in the CTC ward until discharge and consent to the use of sunscreen until the end of the clinical trial (PSV)
• Individuals who have heard a detailed explanation of the trial, fully understand it, voluntarily decide to participate, and provide written consent before the screening examination
• Individuals deemed suitable by the investigator based on medical history, vital signs, 12-lead electrocardiogram (ECG), physical examination, and clinical laboratory tests performed during the screening.

You may not qualify if:

• Individuals with clinically significant diseases or a history of diseases related to the liver, kidney, nervous system, immune system, respiratory system, digestive system, endocrine system, blood/tumors, cardiovascular system, urinary system, mental disorders, etc.
• In the multiple-dose trial, individuals with skin lesions, tattoos on both forearms or show hypersensitivity or allergic reactions to capsaicin cream who may affect the pharmacodynamic evaluation of the investigational product.
• Individuals with gastrointestinal diseases (such as gastrointestinal ulcers, gastritis, gastric spasm, gastroesophageal reflux disease, and Crohn's disease) or a history of surgery that may affect the safety and pharmacokinetic evaluation of the investigational product (excluding simple appendectomy and hernia repair)
• Individuals with a medical history of hypersensitivity reactions to the main active ingredient or components of the investigational product or to drugs in the same class as the main active ingredient
• Individuals with positive results for hepatitis B (HBV) test, hepatitis C (HCV) test, syphilis (RPR) test, or HIV test conducted during screening
• Individuals who exhibited systolic blood pressure \< 80 mmHg or ≥ 140 mmHg or diastolic blood pressure \< 45 mmHg or ≥ 90 mmHg during vital sign measurements in the supine position after a rest period of at least three minutes
• Individuals with a history of drug abuse or who tested positive for drug abuse in the urine drug screening test
• Individuals who have taken prescription drugs or traditional herbal medicine within 2 weeks before the scheduled first dose of the investigational product or have taken any over-the-counter medicines, health-functional foods, or vitamin supplements within 1 week, or are expected to take them
• Individuals who have participated in another clinical trial (including bioequivalence studies) within 6 months before the scheduled first dose of the investigational product
• Individuals who donated blood within 2 months or donated blood components within 1 month, or received a blood transfusion within 1 month before the scheduled first dose of the investigational product
• Individuals who have consumed excessive caffeine (\> 5 units/day) or cannot abstain from consuming caffeine/caffeine-containing foods (such as coffee, tea, carbonated beverages, coffee-flavored milk, energy drinks, etc.) from 3 days before the expected first dose until the end of the clinical trial (PSV)
• Individuals who engage in persistent alcohol consumption (\> 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from alcohol consumption from 3 days before the expected first dose of the investigational product until the end of the clinical trial (PSV) (1 glass (250 mL) of beer (5%) = 10 g, 1 glass (50 mL) of soju (20%) = 8 g, 1 glass (125 mL) of wine (12%) = 12 g)
• Individuals who have smoked more than 10 cigarettes/day within the last 3 months before the scheduled first dose of the investigational product or cannot quit smoking from the screening day until the end of the clinical trial (PSV)
• Individuals who cannot refrain from consuming grapefruit-containing foods from 3 days before the expected first dose of the investigational product until the end of the clinical trial (PSV)
• Individuals who have a pregnancy planning during the entire clinical trial and up to 90 days after the last administration of the investigational product or do not agree to use one or more medically acceptable contraceptive methods. The medically acceptable contraceptive methods are as follows:

Sponsors & Collaborators

• JMackem Co., Ltd: lead
• Seoul National University Hospital: collaborator

Study Sites (1)

Seoul National University Hospital

Seoul, 03080, South Korea

Location

MeSH Terms

Conditions

Neuralgia; Diabetic Neuropathies; Neuralgia, Postherpetic

Interventions

Sagittal Abdominal Diameter; mycophenolic adenine dinucleotide

Condition Hierarchy (Ancestors)

Peripheral Nervous System Diseases; Neuromuscular Diseases; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Body Size; Body Weights and Measures; Body Constitution; Physical Examination; Diagnostic Techniques and Procedures; Diagnosis; Anthropometry; Investigative Techniques; Physiological Phenomena

Study Officials

• Seung-Hwan Lee, MD. Ph.D

  Seoul National University Clinical Trials Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: A randomized, double-blind, placebo-controlled, single and multiple ascending dose

Study Record Dates

• First Submitted: November 16, 2023
• First Posted: December 4, 2023
• Study Start: December 5, 2023
• Primary Completion: April 1, 2025
• Study Completion: September 1, 2025
• Last Updated: October 17, 2024

Record last verified: 2024-10

Locations

KR (1)